Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute2.
作者信息
Narayanan Navaneeth, Mathers Amy J, Wenzler Eric, Moore Nicholas M, Giske Christian G, Mendes Rodrigo E, Edelstein Paul H
机构信息
Department of Pharmacy Practice and Administration, Rutgers University Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA.
Department of Medicine and Pathology, University of Virginia, Charlottesville, Virginia, USA.
出版信息
Clin Infect Dis. 2025 Feb 24;80(2):481-482. doi: 10.1093/cid/ciae246.
Abstract
摘要
相似文献
1
Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute2.
Clin Infect Dis. 2025 Feb 24;80(2):481-482. doi: 10.1093/cid/ciae246.
2
Correction to: Amoxicillin-Clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis. 2025 Jun 4;80(5):e78. doi: 10.1093/cid/ciaf137.
3
Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7. doi: 10.1128/AAC.41.2.292.
4
Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis. 2024 Aug 16;79(2):516-523. doi: 10.1093/cid/ciae201.
5
Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Clin Ther. 2003 Jan;25(1):169-77. doi: 10.1016/s0149-2918(03)90021-x.
6
Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
Antimicrob Agents Chemother. 2004 Jul;48(7):2599-603. doi: 10.1128/AAC.48.7.2599-2603.2004.
7
Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
J Antimicrob Chemother. 2009 Mar;63(3):511-9. doi: 10.1093/jac/dkn538. Epub 2009 Jan 27.
8
Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Antimicrob Agents Chemother. 1998 Dec;42(12):3193-9. doi: 10.1128/AAC.42.12.3193.
9
Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Diagn Microbiol Infect Dis. 2005 Nov;53(3):225-31. doi: 10.1016/j.diagmicrobio.2005.05.001. Epub 2005 Oct 27.
10
Effect of cloned inhibitor-resistant TEM beta-lactamases on the susceptibility of Haemophilus influenzae to amoxicillin/clavulanate.
J Antimicrob Chemother. 2007 Nov;60(5):1151-4. doi: 10.1093/jac/dkm311. Epub 2007 Sep 6.
本文引用的文献
1
Amoxicillin-Clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
Clin Infect Dis. 2024 Aug 16;79(2):516-523. doi: 10.1093/cid/ciae201.
2
Highly variable absorption of clavulanic acid during the day: a population pharmacokinetic analysis.
J Antimicrob Chemother. 2018 Feb 1;73(2):469-476. doi: 10.1093/jac/dkx376.
3
Non-linear absorption pharmacokinetics of amoxicillin: consequences for dosing regimens and clinical breakpoints.
J Antimicrob Chemother. 2016 Oct;71(10):2909-17. doi: 10.1093/jac/dkw226. Epub 2016 Jun 20.
4
Antimicrobial resistance in Haemophilus influenzae.
Clin Microbiol Rev. 2007 Apr;20(2):368-89. doi: 10.1128/CMR.00040-06.
5
Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
J Antimicrob Chemother. 2006 Mar;57(3):536-45. doi: 10.1093/jac/dki480. Epub 2006 Jan 30.
6
Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Antimicrob Agents Chemother. 2005 Mar;49(3):908-15. doi: 10.1128/AAC.49.3.908-915.2005.
7
Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
Antimicrob Agents Chemother. 2004 Sep;48(9):3323-31. doi: 10.1128/AAC.48.9.3323-3331.2004.
8
Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
Antimicrob Agents Chemother. 2004 Jul;48(7):2599-603. doi: 10.1128/AAC.48.7.2599-2603.2004.
9
A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
Clin Ther. 2002 Nov;24(11):1854-70. doi: 10.1016/s0149-2918(02)80084-4.
10
The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Int J Antimicrob Agents. 2002 Aug;20(2):119-29. doi: 10.1016/s0924-8579(02)00126-7.
Zotero 插件